Drug Trial Radar · NCT01096849
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
Last checked: Nov 20, 2026Latest source record: Aug 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Jul 13, 2010
Primary completion
Apr 3, 2012
Study completion Apr 3, 2012
Sponsor
- Lead sponsor
- Achaogen, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary tract infection (cUTI) and acute pyelonephritis (AP).
Conditions
- Complicated Urinary Tract Infection
- Acute Pyelonephritis
Interventions
levofloxacinDrug
plazomicinDrug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) PopulationTime frame: Day 1 to TOC (Day 12)
- Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) PopulationTime frame: Day 1 to TOC (Day 12)
- Percentage of Patients With Treatment-Emergent Adverse Events (TEAE)Time frame: Day 1 to the end of study (Day 40)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.